About: Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19
Creator	Afsin, Abdulmecit Asoglu, Ramazan Ecemis, Kenan
source	Medline; PMC
abstract	BACKGROUND: Limited data are available regarding hydroxychloroquine (HCQ) and moxifloxacin (MOX) in patients with possible coronavirus disease 2019, (COVID-19). Both drugs may increase risk of malignant ventricular arrhythmias associated with prolongation of QT interval. METHODS: A total of 76 subjects with chest tomography findings compatible with COVID-19 pneumonia were enrolled in the study. Standard 12-lead electrocardiogram (ECG) was repeated on days 2 and 5 in patients receiving a combination of HCQ + MOX. Heart rate, QT interval, Tp-e interval, and Tp-e/QT ratio were measured. RESULTS: The mean age of the patients was 61.7 ± 14.8 years and 54% had hypertension. Compared to day 2, ECG on day 5 showed significant increases in QT interval (370.8 ± 32.5 vs. 381.0 ± 29.3, respectively, P = 0.001), corrected QT (QTc) interval (424 (403 - 436) vs. 442 (420 - 468), respectively, P < 0.001), Tp-e interval (60 (55 - 70) vs. 65 (57 - 75), respectively, P < 0.001), cTp-e interval (72.2 ± 12.9 vs. 75.4 ± 12.7, respectively, P < 0.001). Moreover, a slight decrease in Tp-e/QT ratio was observed (0.17 ± 0.03 vs. 0.17 ± 0.02, P = 0.030). QTc was > 500 ms in 5% of the patients, and 8% of patients had an increase in QTc interval > 60 ms. Tp-e/QT ratio was > 0.23 in 4% of patients. Five patients died due to pulmonary failure without evidence of ventricular arrhythmia. No ventricular arrhythmia events, including torsades de pointes (TdP), were observed. CONCLUSIONS: HCQ + MOX combination therapy led to increases in QTc interval, Tp-e interval, and cTp-e interval. However, this therapy did not cause ventricular arrhythmia in the short-term observation.
has issue date	2020-08-15(xsd:dateTime)
bibo:doi	10.14740/jocmr4288
bibo:pmid	32849949
has license	cc-by-nc
sha1sum (hex)	b512c5158a7efb3b4d7d1730a3f9726459e1f0d1
schema:url	https://doi.org/10.14740/jocmr4288
resource representing a document's title	Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19
has PubMed Central identifier	PMC7430923
has PubMed identifier	32849949
schema:publication	J Clin Med Res
resource representing a document's body	covid:b512c5158a7efb3b4d7d1730a3f9726459e1f0d1#body_text
is schema:about of	named entity 'patients' named entity 'COVID-19' named entity 'MOX' named entity 'Plus' named entity 'hydroxychloroquine' named entity 'moxifloxacin' named entity 'Moxifloxacin' named entity 'medical community' named entity 'breast-feeding' named entity 'HCQ' named entity 'repolarization' named entity 'TdP' named entity 'cardiologists' named entity 'PCR test' named entity 'Republic of Turkey' named entity 'QT interval' named entity 'COVID' named entity 'ECG' named entity 'COVID' named entity 'COVID' named entity 'PCR test' named entity 'arrhythmia' named entity 'combination therapy' named entity 'QTc' named entity 'prolonged QT' named entity 'ventricular arrhythmia' named entity 'clinical studies' named entity 'QTc' named entity 'electrocardiogram' named entity 'ECG' named entity 'electronic medical records' named entity 'QT interval' named entity 'syncope' named entity 'action potential' named entity 'QT interval' named entity 'rheumatoid arthritis' named entity 'dysrhythmic' named entity 'QTc' named entity 'Holter monitor' named entity 'single center' named entity 'TdP' named entity 'chloroquine' named entity 'Long QT' named entity 'Chicago' named entity 'ECG' named entity 'platelet counts' named entity 'COVID-19' named entity 'D-dimer' named entity 'combination therapy' named entity 'QTc' named entity 'repolarization' named entity 'SPSS Inc.' named entity 'SARS-CoV-2' named entity 'Denmark' named entity 'QT interval' named entity 'ventricular arrhythmia' named entity 'statistically significant' named entity 'HERG' named entity 'repolarization' named entity 'repolarization' named entity 'Randomized controlled studies' named entity 'cardiovascular' named entity '12-lead ECG' named entity 'outpatient clinic' named entity 'Copenhagen' named entity 'ECG' named entity 'comorbidity' named entity 'coronavirus' named entity 'Philips' named entity 'atrial arrhythmia' named entity 'broad-spectrum antibiotic' named entity 'tricyclic antidepressants' named entity 'repolarization' named entity 'ECGs' named entity 'COVID-19' named entity 'HCQ' named entity 'ECG' named entity 'prolonged QT' named entity 'QT interval'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software